Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas

Bone Marrow Transplantation volume 51, pages 1617–1619 (2016)Cite this article

Subjects

Peripheral T-cell lymphomas (PTCL) account for 10 to 15% of all non-Hodgkin lymphomas worldwide.1 Outcome for most PTCL patients is poor after conventional anthracycline-based regimens with 5-year overall survival probabilities of 30 to 40% in most studies.2, 3, 4 High-dose chemotherapy with autologous stem cell transplantation (ASCT) in first CR (CR1) or for refractory disease is widely used, although most patients will still relapse after the procedure. Even when done in CR1, more than half of PTCL patients who undergo ASCT relapse and succumb from their disease,5 likely explained by the persistence of the malignant clone at the time of ASCT.

The detection of molecular MRD in ALK-positive anaplastic large cell lymphoma (ALCL) has been established as a strong predictor of treatment failure and imminent clinical relapse.6 The evaluation of MRD in other PTCL subtypes has not been reported. In this study, we retrospectively investigated the prognostic impact of minimal detectable disease (MDD) on the outcome of 29 PTCL patients undergoing ASCT at our institutions using an innovative multi-parameter flow cytometry approach.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Swerdlow SH, CE HN et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008.

    Google Scholar 

  2. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F . Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520.

    CAS  PubMed  Google Scholar 

  3. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82.

    CAS  PubMed  Google Scholar 

  4. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475.

    Article  CAS  Google Scholar 

  5. Yared J, Kimball A . The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 2013; 39: 51–59.

    Article  CAS  Google Scholar 

  6. Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2014; 123: 334–337.

    Article  CAS  Google Scholar 

  7. Wood B . 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006; 130: 680–690.

    PubMed  Google Scholar 

  8. Wu D, Allen CT, Fromm JR . Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. Cytometry B Clin Cytom 2015; 88: 58–63.

    Article  Google Scholar 

  9. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165–173.

    Article  CAS  Google Scholar 

  10. Wu D, Anderson MM, Othus M, Wood BL . Clinical experience with modified, single-tube T-cell receptor vbeta flow cytometry analysis for T-cell clonality. Am J Clin Pathol 2016; 145: 467–485.

    Article  CAS  Google Scholar 

  11. Moskowitz AJ, Lunning MA, Horwitz SM . How I treat the peripheral T-cell lymphomas. Blood 2014; 123: 2636–2644.

    Article  CAS  Google Scholar 

  12. Dogan A, Morice WG . Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127: 140–154.

    Article  Google Scholar 

  13. Moss TJ, Ross AA . The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225–232.

    Article  CAS  Google Scholar 

  14. Kruger W, Kroger N, Togel F, Badbaran A, Renges H, Gieseking F et al. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells. J Hematother Stem Cell Res 2001; 10: 303–307.

    Article  CAS  Google Scholar 

  15. Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003; 32: 307–311.

    Article  CAS  Google Scholar 

  16. Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH . Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001; 116: 512–526.

    Article  CAS  Google Scholar 

  17. Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D et al. Flow cytometric immunophenotypic assessment of T-cell clonality by Vbeta repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. Am J Clin Pathol 2011; 135: 890–900.

    Article  CAS  Google Scholar 

  18. Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012; 4: 134ra63.

    Article  Google Scholar 

  19. Schumacher JA, Duncavage EJ, Mosbruger TL, Szankasi PM, Kelley TW . A comparison of deep sequencing of TCRG rearrangements vs traditional capillary electrophoresis for assessment of clonality in T-Cell lymphoproliferative disorders. Am J Clin Pathol 2014; 141: 348–359.

    Article  CAS  Google Scholar 

  20. Shustov A, Cherian S, Shaw A, Lupinacci TA, Maloney D, Holmberg L et al. In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation. Br J Haematol 2011; 154: 415–418.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA

    J Gauthier, L Holmberg, W Bensinger, A K Gopal, O Press, D Maloney, D J Green, B G Till & A Shustov

  2. CHRU Lille, Pôle spécialités médicales et gérontologie, service des Maladies du Sang, secteur allogreffe de cellules souches hématopoïétiques, Lille, France

    J Gauthier

  3. Université de Lille, UFR Médecine, Lille, France

    J Gauthier

  4. Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA,

    L Holmberg, W Bensinger, A K Gopal, O Press, D Maloney, D J Green & B G Till

  5. Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA, USA,

    D Wu

  6. Division of Haematology, University of Washington School of Medicine, Seattle, WA, USA

    D Byelykh & A Shustov

Authors
  1. J Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Holmberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Bensinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A K Gopal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Press
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Maloney
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D J Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B G Till
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Byelykh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Shustov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Shustov.

Ethics declarations

Competing interests

Gopal AK: Merck: Research Funding; Emergent/Abbott: Research Funding; Cephalon/Teva: Research Funding; BioMarin: Research Funding; Sanofi-Aventis: Honoraria; Millenium: Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Spectrum: Consultancy, Research Funding; Gilead: Consultancy, Research Funding; Piramal: Research Funding; Biogen Idec, BMS: Research Funding. Maloney D: Juno Therapeutics: Research Funding; Roche/Genentech: Honoraria; Janssen Scientific Affairs: Honoraria; Seattle Genetics: Honoraria. Till: Roche-Genentech: Research Funding. Shustov A: Celgene: Honoraria and consultancy, Spectrum and BMS: consultancy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gauthier, J., Holmberg, L., Wu, D. et al. Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas. Bone Marrow Transplant 51, 1617–1619 (2016). https://doi.org/10.1038/bmt.2016.227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.227

This article is cited by

Search

Advanced search

Quick links